<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0CF6353C-24C9-4866-99CF-FB1DB633AF6F"><gtr:id>0CF6353C-24C9-4866-99CF-FB1DB633AF6F</gtr:id><gtr:name>University of North Carolina at Chapel Hill</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4B8017E5-40E0-4ED8-9216-7010746F9003"><gtr:id>4B8017E5-40E0-4ED8-9216-7010746F9003</gtr:id><gtr:name>Institute of Cancer Research UK</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/63C3968A-F903-4D7A-8EFB-D9A237129852"><gtr:id>63C3968A-F903-4D7A-8EFB-D9A237129852</gtr:id><gtr:name>Marie Curie</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/68FB3A84-29CE-4F10-B27B-1482AD81759C"><gtr:id>68FB3A84-29CE-4F10-B27B-1482AD81759C</gtr:id><gtr:name>Beatson Institute for Cancer Research</gtr:name><gtr:department>Research Group 18 (Owen Sansom)</gtr:department><gtr:address><gtr:line1>Garscube Estate</gtr:line1><gtr:line2>Switchback Road, Bearsden</gtr:line2><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G61 1BD</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68FB3A84-29CE-4F10-B27B-1482AD81759C"><gtr:id>68FB3A84-29CE-4F10-B27B-1482AD81759C</gtr:id><gtr:name>Beatson Institute for Cancer Research</gtr:name><gtr:address><gtr:line1>Garscube Estate</gtr:line1><gtr:line2>Switchback Road, Bearsden</gtr:line2><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G61 1BD</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0CF6353C-24C9-4866-99CF-FB1DB633AF6F"><gtr:id>0CF6353C-24C9-4866-99CF-FB1DB633AF6F</gtr:id><gtr:name>University of North Carolina at Chapel Hill</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4B8017E5-40E0-4ED8-9216-7010746F9003"><gtr:id>4B8017E5-40E0-4ED8-9216-7010746F9003</gtr:id><gtr:name>Institute of Cancer Research UK</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/63C3968A-F903-4D7A-8EFB-D9A237129852"><gtr:id>63C3968A-F903-4D7A-8EFB-D9A237129852</gtr:id><gtr:name>Marie Curie</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/ED605267-F7C1-4C36-B3E0-896404E29464"><gtr:id>ED605267-F7C1-4C36-B3E0-896404E29464</gtr:id><gtr:firstName>Colin</gtr:firstName><gtr:otherNames>Rowan</gtr:otherNames><gtr:surname>Lindsay</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0901991"><gtr:id>B9A5D1A6-BFAD-4386-8DDC-A4DC61ECCE05</gtr:id><gtr:title>Investigating the role of P-Rex1 in mouse models of melanoma</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0901991</gtr:grantReference><gtr:abstractText>The skin cancer malignant melanoma (MM) is increasing in rate more than any other common cancer in the UK, and is doubling in rate every 10-20 years in Western countries. Early spread of MM to other organs is nearly always the cause of death from this cancer. Identifying and studying new proteins which are both responsible for this spread and treatable is crucial for this cancer which is known for being unresponsive to traditional therapies.

We have genetically removed a protein called P-Rex1 from black mice, and discovered that their bellies and feet remain white. These white areas suggest that melanocytes (the skin cells responsible for MM) aren?t reaching the furthest regions of migration during normal mouse development. We also know that the genetic changes required for melanocyte movement during development are very similar to the genetic changes required during MM tumour spread. Therefore we have obtained mice which develop human-like melanomas and I plan to assess if removing P-Rex1 can stop the lethal migration of melanocytes (known as metastasis) to other organs. I will also analyse resected human melanoma specimens to evaluate P-Rex1 in a comprehensive manner which is correlated with how well the patient did with their melanoma.</gtr:abstractText><gtr:technicalSummary>Aims: The incidence of malignant melanoma (MM) is increasing more than any other common cancer in the UK. Worldwide its incidence is doubling in rate every 10-20 years in countries with white populations. Metastasis is almost invariably the ultimate cause of death in MM. My aim is to study the impact of P-Rex1 on metastasis in humanised mouse models of melanoma.

Hypothesis: Several humanised mouse models of human melanoma have been characterised, reflecting both common gain-of-function mutations (BrafV600E, NrasQ61K) as well as loss-of-function in known MM tumour-suppressor genes (PTEN, CDKN2A). We have crossed a P-Rex1 knockout mouse to a pure C57BL6 background, revealing a previously uncharacterised ?white belly? phenotype with matching white feet and tail. These areas are the extremities of melanoblast migration during embryogenesis, suggesting a migratory deficit of the cells. Previous work done in our laboratory has also shown P-Rex1 to be consistently up-regulated in a host of melanoma cell lines. I therefore hypothesised that P-Rex1 up-regulation is a central component of the melanocyte migration involved in melanoma metastasis.

Objectives: 
1. To study incidence, latency, and localisation of MM primary tumours and metastasis between P-Rex1 knockout and WT mice crossed to both BrafV600E and NrasQ61K melanoma mouse models.
2. To apply both GFP and DCT-lacZ reporter constructs to the above genotypes in order to study melanoblast migration as a paradigm for MM metastasis.
3. To perform a comprehensive survey of P-Rex1 expression in a host of human melanoma samples (including tissue microarrays) and correlate with outcome data.

Design &amp;amp; Methodology: 
We already have access to characterised BrafV600E and NrasQ61K mouse models of MM, as well as P-Rex1 knockout mice. With these mice I plan to perform a comprehensive cohort comparison study to answer my hypothesis with regard to objective 1. To fully characterise the MM model(s) I will use histologicnd immunohistochemistry (IHC) techniques. The transgenic expression of GFP or ?-galactosidase under the control of melanocyte-specific promoters will allow me to assess morphology, speed, and localisation of melanoblasts in various forms of MM genetically modified mice. I will further consolidate the importance of these signalling pathways using clinical MM tissue microarrays (TMA) to explore the role of P-Rex1 in primary and metastatic human samples.

Medical and Scientific Opportunities: Identifying and characterising novel proteins which are responsible for metastasis and amenable to therapeutic intervention is a priority for MM, which is characterised by its resistance to traditional chemotherapeutics and ability to metastasise early.</gtr:technicalSummary><gtr:fund><gtr:end>2012-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>212562</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Marie Curie</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Marie Curie Research Institute</gtr:department><gtr:description>Institut Curie, Paris</gtr:description><gtr:id>C2F39114-1050-42E9-BA72-941849E9D478</gtr:id><gtr:impact>one paper due for submission within 2 weeks</gtr:impact><gtr:outcomeId>XQsJAfAoYNZ-1</gtr:outcomeId><gtr:partnerContribution>Provided Tyr Cre mice, offered advice and expertise.</gtr:partnerContribution><gtr:piContribution>Tyr Cre mice essential to cancer cohort and reporter studies described in grant application. Allows melanocyte-specific expression of various mutations of interest.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Inflammation Research</gtr:department><gtr:description>MRC, Edinburgh</gtr:description><gtr:id>35D6644C-C48E-4D94-AE65-7A360F985547</gtr:id><gtr:impact>Similar interests between collaborators, so I wouldnt describe as multi-disciplinary.

One paper so far is due for submission in next 2 weeks.</gtr:impact><gtr:outcomeId>HSZnZJ4327P-1</gtr:outcomeId><gtr:partnerContribution>Provided DCT-lacZ mice, offered expertise and advice</gtr:partnerContribution><gtr:piContribution>DCT-lacZ mice now bred to Prex mice and embryological studies at an advanced stage.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ICR, London</gtr:description><gtr:id>B3FC2000-529F-48A6-B93F-092373BE3572</gtr:id><gtr:impact>one paper do far, due for submission within 2 wks.</gtr:impact><gtr:outcomeId>oYSr1kRVMSM-1</gtr:outcomeId><gtr:partnerContribution>Provided oncogenic Braf mice for breeding to Prex mice</gtr:partnerContribution><gtr:piContribution>Braf mice at an advanced stage of breeding with Prex mice central to grant application. Various comparisons of cancer characteristics between Prex wild-type and knockout mice are underway.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of North Carolina at Chapel Hill</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>University of North Carolina</gtr:description><gtr:id>B7A5898E-C9D9-4568-AC0D-C4F0FCAECD50</gtr:id><gtr:impact>paper due for submission within 2 wks.</gtr:impact><gtr:outcomeId>kkCCXUcVPYy-1</gtr:outcomeId><gtr:partnerContribution>Examining human tissue immunohistochemically, offering expertise and advice</gtr:partnerContribution><gtr:piContribution>Collaborative immunohistochemistry, co-ordinated between 2 centres</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Beatson Institute Open Evening</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:id>F7F991EA-1456-40F6-8010-E8961BF3FEC7</gtr:id><gtr:impact>Approximately 10 people attended a tour of the institute with myself. These consisted of school pupils, as well as patients and relatives affected by cancer. I used my MRC-funded research as an example of how translational cancer is performed here.

I have been asked to participate in such events again in the future, and will likely be presenting to larger public audiences at some point.</gtr:impact><gtr:outcomeId>DNxjv8kRqCM</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Murine melanoma allograft development</gtr:description><gtr:geographicReach>Local/Municipal/Regional - UK Only</gtr:geographicReach><gtr:id>61DBEC81-E987-4758-838A-138D954486BE</gtr:id><gtr:impact>I have led development and characterisation of murine melanoma allografts following subcutaneous and tail-vein injection of immuno-competent mice. I have disseminated my experience to other groups within the institute, primarily to advise how they can best use in vivo models of melanoma to characterise their tissue culture results.</gtr:impact><gtr:outcomeId>GZQqE9F1gxa</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Cell lines derived from murine melanocytes (described previously) re-injected into immuno-competent C57Bl6 mice by both subcutaneous and tail-vein routes. Served as nice models of primary and metastatic melanomagenesis for with which we could apply genetic manipulations.</gtr:description><gtr:id>9043DF56-3697-46A2-9DF5-1A11B9D70243</gtr:id><gtr:impact>Results in recent Nature Comms paper.</gtr:impact><gtr:outcomeId>b1S7ZVNv6ef</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>murine melanoma allograft model</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Cell lines derived from pup skin of various Nras and Prex genotypes</gtr:description><gtr:id>485ABDD5-8E28-4E1D-827E-ED082C1C3DB9</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>Z2kQfxbseCF</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Nras Prex melanocyte cell lines</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Melanoblast migration and cell number assays using DCT-lacZ mice</gtr:description><gtr:id>2C0C27C9-A46C-47AE-A24E-7961C465CAC4</gtr:id><gtr:impact>results in recent Nature Comms paper</gtr:impact><gtr:outcomeId>Dx2stYA2jG1</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Melanoblast migration and cell number assays</gtr:title><gtr:type>Data analysis technique</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Assays developed to study dynamic characteristics of melanoblast movement using live imaging</gtr:description><gtr:id>DA588E98-9AE5-47E8-BA11-D61159ECCA1D</gtr:id><gtr:impact>results in recent Nature Comms paper</gtr:impact><gtr:outcomeId>r89FWjiNXxq</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Melanoblast speed and distance assays</gtr:title><gtr:type>Data analysis technique</gtr:type><gtr:yearFirstProvided>2011</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>8CEB4617-C14C-48B5-BB43-0662BCAC1681</gtr:id><gtr:title>P-Rex1 is required for efficient melanoblast migration and melanoma metastasis.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9c3b9450c247f4ad2f89681513fdbda"><gtr:id>d9c3b9450c247f4ad2f89681513fdbda</gtr:id><gtr:otherNames>Lindsay CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>dovkKn16inR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF7DA4BE-89BA-4F75-87D4-36B3D8CA624B</gtr:id><gtr:title>Rac1 drives melanoblast organization during mouse development by orchestrating pseudopod- driven motility and cell-cycle progression.</gtr:title><gtr:parentPublicationTitle>Developmental cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c5c2253c4ba1d1ab5829aa152019a46"><gtr:id>7c5c2253c4ba1d1ab5829aa152019a46</gtr:id><gtr:otherNames>Li A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1534-5807</gtr:issn><gtr:outcomeId>rp5GRFGiWVa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7DDC55E6-F2D0-46D5-BBCC-1E4CDE0023C7</gtr:id><gtr:title>Melanoma cells break down LPA to establish local gradients that drive chemotactic dispersal.</gtr:title><gtr:parentPublicationTitle>PLoS biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f74e18abfb905c3f3ec881f9b1087dc"><gtr:id>3f74e18abfb905c3f3ec881f9b1087dc</gtr:id><gtr:otherNames>Muinonen-Martin AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1544-9173</gtr:issn><gtr:outcomeId>58c9bda8cbd409.37826652</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54DB202A-4324-4EDB-A906-0BFBAB2F22EA</gtr:id><gtr:title>A Rac1-independent role for P-Rex1 in melanoblasts.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d9c3b9450c247f4ad2f89681513fdbda"><gtr:id>d9c3b9450c247f4ad2f89681513fdbda</gtr:id><gtr:otherNames>Lindsay CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>58c9bda875a8a7.66443587</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0901991</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>